Online Library: Retinitis pigmentosa
The following pages provide an overview of the most recent research and clinical studies about the health benefits of micronutrients in fighting Retinitis pigmentosa . This collection of scientific facts proves that anyone who privately or publicly questions the health value of micronutrients does not serve YOUR health, or the health of the people, but rather the multi-billion dollar investment 'business with disease' based on patented pharmaceutical drugs.
We encourage you to forward the link to this important online library on natural health – one of the largest ones in the world – to your friends. You may also print out the articles you find most important for your own health condition and share them with your doctor. Any responsibly acting health professional will be grateful to receive such science-based health education.
Treatment with 9-cis â-carotene-rich powder in patients with retinitis pigmentosa: a randomized crossover trial.
Affiliation: Maurice and Gabriela Goldschleger Eye Research Institute, Tel-Hashomer, Israel.
Abstract: Retinitis pigmentosa (RP) is the leading cause of incurable inherited blindness in the developed world, with an estimated prevalence of 1 in 3500 individuals. Therefore, it is important to develop new treatments for this disease. The objective was to determine the effect of oral treatment with 9-cis â-carotene on visual function of patients with RP in a randomized, double-masked, placebo-controlled, crossover clinical trial. Thirty-four patients with RP who were at least 18 years of age were observed. Twenty-nine patients completed the study and were included in the analysis. Patients were treated daily for 90 days with capsules containing 300 mg of 9-cis â-carotene-ich alga Dunaliella bardawil (â-carotene, approximately 20 mg) or placebo (starch). Following a 90-day washout period, they were treated for 90 days with the other capsules. The primary outcome was the change for both eyes from baseline to the end of each treatment in dark-adapted maximal electroretinographic b-wave amplitude. The secondary outcomes were the changes in light-adapted maximal b-wave amplitude, dark- and light-adapted visual field, and best-corrected visual acuity. The mean change in dark-adapted maximal b-wave amplitude relative to initial baseline was +8.4 ìV for 9-cis â-carotene vs −.9 ìV for placebo. Ten participants (34.5%) had an increase of more than 10 ìV for both eyes after 9-cis â-carotene treatment compared with no participants after placebo treatment. The percentage change in light-adapted b-wave response was +17.8%for 9-cis â-carotene vs −.0% for placebo. No significant differences were found between the groups for visual field and best-corrected visual acuity. No adverse effects were observed. Conclusion: Treatment with 9-cis â-carotene significantly increased retinal function in patients with RP under the tested conditions.